At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 678 enrolled
Drug / intervention
Influenza Vaccine GSK1247446A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate Compared to Fluarix™ Administered Intramuscularly in Elderly Aged 60 Years and Above.
In Brief
A Phase 2 clinical trial evaluating Influenza Vaccine GSK1247446A and FluarixTM for Influenza. Completed, enrolled 678 participants across 4 sites.
Detailed Summary
The purpose of this study is to evaluate the immunogenicity and the safety of a second vaccination with candidate vaccine compared to Fluarix™ administered intramuscularly in elderly aged 60 years and above
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesNorway
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartOct 2006
Primary CompletionFeb 2007
Study CompletionFeb 2007
TodayJul 2026
First PostedOct 11, 2006
Enrollment StartOct 20, 2006
Primary CompletionFeb 1, 2007
Study CompletionFeb 5, 2007
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 19.7 years ago
Interventions
Influenza Vaccine GSK1247446Abiological
Single dose, intramuscular injection
FluarixTMbiological
Single dose, intramuscular injection